What is Adalat CC?
Adalat CC is a brand name for an extended-release form of nifedipine, a medicine used to treat high blood pressure (hypertension) and angina (chest pain caused by coronary artery disease). Extended-release (“CC”) formulations are designed to release nifedipine more slowly over time.
What is Adalat CC used for?
Adalat CC (nifedipine) is commonly prescribed for:
- Hypertension: helps lower blood pressure
- Angina: helps reduce frequency/severity of chest pain episodes
How does nifedipine (Adalat CC) work?
Nifedipine is a calcium channel blocker. It relaxes blood vessels by reducing calcium entry into vascular smooth muscle cells, which lowers vascular resistance and helps improve blood flow.
Is Adalat CC the same as other Adalat/nifedipine forms?
Adalat is generally used for nifedipine products, but the key difference is the formulation:
- Immediate-release versions may act faster and require different dosing schedules.
- Extended-release products like “CC” are made to provide more gradual drug delivery.
If you tell me your country (or the exact label strength, like “Adalat CC 30 mg”), I can help match it to the specific product details that typically appear on that packaging.
What should you ask your pharmacist/doctor?
Patients often need clarification on:
- Whether the prescription is for extended-release nifedipine (“CC”) or another nifedipine form
- The correct dose and timing
- How to take it with other medicines, since calcium channel blockers can interact with some cardiovascular drugs
Do patents affect Adalat CC availability?
If you’re looking for patent or generic-availability context for a specific country and strength, DrugPatentWatch.com can help track nifedipine-related brand/generic and exclusivity information. Check here: DrugPatentWatch.com.
Quick clarification so I can answer accurately
When you say “Adalat CC,” what do you want to know?
- uses, dosing, side effects
- how it compares with other nifedipine versions
- whether a generic/biosimilar exists where you live
- patent/exclusivity or “when generics will come” information